Docetaxel-related skin, nail, and vascular toxicity.
Leonard
Gregory D
GD
Medical Oncology Clinical Research Unit, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1960, USA. leonardg@mail.nih.gov
Zujewski
Jo Anne
JA
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D000077143:Docetaxel; D005260:Female; D005542:Forearm; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009260:Nail Diseases / Q000139:chemically induced*; D017239:Paclitaxel / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010689:Phlebitis / Q000139:chemically induced*; D012871:Skin Diseases / Q000139:chemically induced*; D043823:Taxoids; D014034:Toes
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel